GeoVax Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GOVX Nasdaq 2836 www.geovax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GeoVax Labs, Inc.

GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Aug 6th, 2026 7:00 am
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Aug 3rd, 2026 7:00 am
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - Jul 27th, 2026 2:00 pm
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Jul 21st, 2026 7:00 am
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness - Jul 1st, 2026 7:00 am
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - Jun 27th, 2026 8:07 am
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers - Jun 17th, 2026 7:00 am
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Jun 12th, 2026 7:55 am
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses - Jun 8th, 2026 7:00 am
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation - Jun 3rd, 2026 7:00 am
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness - Jun 1st, 2026 7:15 am
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - May 28th, 2026 9:00 am
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event - May 27th, 2026 7:00 am
Why Is GOVX Stock Falling Today? - May 26th, 2026 9:45 am
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R) - May 26th, 2026 5:30 am
How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks - May 26th, 2026 5:08 am
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms - May 20th, 2026 8:00 am
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats - May 18th, 2026 12:30 pm
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules - May 18th, 2026 10:46 am
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy - May 15th, 2026 10:00 am